Oncotarget

Clinical Research Papers:

Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study

Yu-Hsiang Chiu, Chi-Hsiang Chung, Kuen-Tze Lin, Chin-Sheng Lin, Jia-Hong Chen, Hsiang-Cheng Chen, Ren-Yeong Huang, Chi-Tsung Wu, Feng-Cheng Liu and Wu-Chien Chien _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:50098-50108. https://doi.org/10.18632/oncotarget.15100

Metrics: PDF 1047 views  |   HTML 1579 views  |   ?  


Abstract

Yu-Hsiang Chiu1, Chi-Hsiang Chung2, Kuen-Tze Lin3, Chin-Sheng Lin4, Jia-Hong Chen5, Hsiang-Cheng Chen1, Ren-Yeong Huang6, Chi-Tsung Wu7, Feng-Cheng Liu1 and Wu-Chien Chien2,8

1 Department of Internal Medicine, Division of Rheumatology/Immunology/Allergies, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

2 School of Public Health, National Defense Medical Center, Taipei, Taiwan

3 Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

4 Department of Internal Medicine, Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

5 Department of Internal Medicine, Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

6 Department of Periodontology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

7 Department of Oral and Maxillofacial Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

8 Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Correspondence to:

Wu-Chien Chien, email:

Feng-Cheng Liu, email:

Keywords: Sjögren syndrome, non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma, immunosuppressive agents, lip biopsy

Received: August 04, 2016 Accepted: January 23, 2017 Published: February 04, 2017

Abstract

Sjögren syndrome (SS) is commonly known to be correlated with lymphoma. This study included 16,396 individuals in the SS cohort and 65,584 individuals in the non-SS cohort, all of whom were enrolled in the Taiwan National Health Insurance database between 2000 and 2010. We evaluated the risk factors of non-Hodgkin’s lymphoma (NHL) in the primary SS cohort by applying a Cox multivariable proportional-hazards model. We increased the correlation of patients with SS and NHL, with an adjusted HR of 4.314 (95% CI 2.784 – 6.685). Of the 16,396 SS patients, 66 individuals had salivary gland slices without NHL development, while the other 16,330 individuals that did not have salivary gland slices revealed 30 individuals that developed NHL. Of the 16,396 SS patients, 128 individuals underwent immunomodulator agent therapy (including hydroxychloroquine, azathioprine, cyclosporine, methotrexate, and rituximab) without NHL development. None of the 30 individuals that developed NHL from SS received immunomodulator agents. We found that patients with SS were at an increased risk of developing NHL, with the most common NHL subgroup being diffused large B-cell lymphoma. SS patients who were candidates for salivary gland slices or immunomodulator agents were associated with a lower risk of developing lymphoma over time. We recommend that patients at a higher risk upon diagnosis of SS receive close follow-up and aggressive treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15100